Modulating effects of RAMPs on signaling profiles of the glucagon receptor family

Lijun Shao\textsuperscript{a,b,c}, Yan Chen\textsuperscript{d}, Shikai Zhang\textsuperscript{e}, Zhihui Zhang\textsuperscript{e}, Yongbing Cao\textsuperscript{e}, Dehua Yang\textsuperscript{a,b,c,*}, Ming-Wei Wang\textsuperscript{a,b,c,d,f,*}

\textsuperscript{a}The National Center for Drug Screening and CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai 201203, China
\textsuperscript{b}School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China
\textsuperscript{c}University of Chinese Academy of Sciences, Beijing 100049, China
\textsuperscript{d}School of Pharmacy, Fudan University, Shanghai 201203, China
\textsuperscript{e}Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200082, China
\textsuperscript{f}Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China

Received 25 January 2021; received in revised form 4 June 2021; accepted 7 July 2021

KEY WORDS
G protein-coupled receptor; Glucagon receptor family; Receptor activity-modulating protein; Signaling; Allosteric modulation; GPCR–RAMP interaction;

Abstract  Receptor activity-modulating proteins (RAMPs) are accessory molecules that form complexes with specific G protein-coupled receptors (GPCRs) and modulate their functions. It is established that RAMP interacts with the glucagon receptor family of GPCRs but the underlying mechanism is poorly understood. In this study, we used a bioluminescence resonance energy transfer (BRET) approach to comprehensively investigate such interactions. In conjunction with cAMP accumulation, G\textsubscript{a}\textsubscript{q} activation and \(\beta\)-arrestin1/2 recruitment assays, we not only verified the GPCR–RAMP pairs previously reported, but also identified new patterns of GPCR–RAMP interaction. While RAMP1 was able to modify the three signaling events elicited by both glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R), and RAMP2 mainly affected \(\beta\)-arrestin1/2 recruitment by GCGR, GLP-1R and glucagon-like peptide-2 receptor, RAMP3 showed a widespread negative impact on all the family

Abbreviations: AMY, amylin; \(B_{\text{max}}\), maximum measured BRET value; BRET, bioluminescence resonance energy transfer; \(\beta\text{-AR}\), \(\beta\)-adrenergic receptor; cAMP, cyclic adenosine monophosphate; CGRP, calcitonin gene-related peptide; CLR, calcitonin-like receptor; EC\textsubscript{50}, half maximal effective concentration; ECD, extracellular domain; \(E_{\text{max}}\), maximal response; GCGR, glucagon receptor; GHRHR, hormone-releasing hormone receptor; GIPR, gastric inhibitory polypeptide receptor or glucose-dependent insulinotropic polypeptide; GLP-1R, glucagon-like peptide-1 receptor; GLP-2R, glucagon-like peptide-2 receptor; GPCRs, G protein-coupled receptors; pEC\textsubscript{50}, negative logarithm of EC\textsubscript{50}; RAMP, receptor activity-modulating protein; Rhc, \textit{Resilia} luciferase; SBA, suspension bead array; SCTR, secretin receptor; SV, splice variant; TMD, transmembrane domain; VPAC2R, vasoactive intestinal polypeptide 2 receptor.

*Corresponding authors.
E-mail addresses: dhyang@simm.ac.cn (Dehua Yang), mwwang@simm.ac.cn (Ming-Wei Wang).

Peer review under responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

https://doi.org/10.1016/j.apsb.2021.07.028
2211-3835 © 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Receptor activity-modulating proteins (RAMPs) are a family of single transmembrane protein represented by three subtypes, RAMP1, 2 and 3. It has a conserved transmembrane domain, one large extracellular N terminus (~150 amino acids) and a short intracellular C terminus (~9 amino acids). RAMP was first found to bind with calcitonin-like receptor (CLR) and is required for CLR translocation from the endoplasmic reticulum to the cell membrane. Combination of CLR with RAMP1 forms the calcitonin gene-related peptide (CGRP) receptor complex, and that with RAMP2 and RAMP3 constitutes adrenomedullin receptors 1 and 2, respectively. RAMP, as a member of accessory proteins, interacts with G protein-coupled receptor (GPCR) and displays receptor-dependent functional modulation of trafficking, selectivity and signaling. For instance, association of the calcitonin receptor with RAMPs 1–3 yields three amylin (AMY) receptors: AMY1R, AMY2R and AMY3R, respectively. Using different methods that monitor receptor trafficking subsequently identified interactions between other GPCRs and RAMPs, including glucagon receptor (GCGR), parathyroid hormone 1 and 2 receptors, vasoactive intestinal polypeptide 1 and 2 receptors (VIPAC2R), corticotropin-releasing factor receptor 1 and secretin receptor (SCTR). Recently established suspension bead array immunoassay (SBA) of protein–protein interaction significantly expanded GPCR–RAMP pairs to cover all of the class B1 receptors.

The glucagon receptor family includes GCGR, growth hormone-releasing hormone receptor (GHRHR), gastrin inhibitory polypeptide receptor (GIPR), glucagon-like peptide-1 and -2 receptors (GLP-1R and GLP-2R) and secretin receptor (SCTR). Studies of GPCR–RAMP interactions will deepen our knowledge of receptor pharmacology that is valuable for the design of better therapeutics. We, therefore, investigated the effects of RAMP on signaling profiles (cAMP accumulation, Goα-mediated cyclic adenosine monophosphate (cAMP) accumulation, Goα-mediated intracellular Ca2+ mobilization and G protein-independent β-arrestin1/2 recruitment)

Studies of GPCR–RAMP interactions will deepen our knowledge of receptor pharmacology that is valuable for the design of better therapeutics. We, therefore, investigated the effects of RAMP on signaling profiles (cAMP accumulation, Goα activation and β-arrestin1/2 recruitment) mediated by the six members of this receptor family upon stimulation by endogenous ligands (glucagon, oxyntomodulin, GHRH, GIP, GLP-1, GLP-2 and secretin). A bioluminescence resonance energy transfer (BRET) assay was employed, instead of SBA, described in the literature, to measure the GPCR–RAMP interaction. Besides, SV1, a splice variant (SV) of GHRHR, was examined for comparison with the full-length receptor. Our results demonstrate that the association of the glucagon receptor family and RAMPs are broad and RAMPs specifically modulate their signaling profiles except for GHRHR.

2. Material and methods

2.1. Constructs

Full-length cDNA of the human CLR, vectors of the human RAMP1 and RAMP2, vectors of the human FLAG-RAMP1 and FLAG-RAMP2, as well as plasmids for the BRET assay were provided by Dr. Patrick M. Sexton. Plasmids used in the NanoBiT assay were gifts from Dr. Asuka Inoue. Full-length cDNA of the human RAMP3 was obtained from BGI (Beijing, China). Addition of FLAG- and HA-tags to receptors or RAMP3 was carried out by site-directed mutagenesis. All receptors were cloned to pcDNA3.1 vector and to the backbone of Renilla luciferase 8 (Rluc8) at the C terminus. RAMPs 1, 2 and 3 were ligated into both Ypet-N1 vector and pcDNA3 expression plasmid, respectively. All constructs were confirmed by DNA sequencing (GENEWIZ, Suzhou, China).

2.2. Cell culture

COS-7 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum ( Gibco) and 100 mmol/L sodium pyruvate (Gibco). HEK293A cell line was provided by Dr. Patrick M. Sexton and maintained in DMEM supplemented with 10% fetal bovine serum and nonessential amino acids (Gibco). All cell lines were incubated in a humidified environment at 37 °C in 5% CO2.

For transient transfection, cells were seeded in either 6-well or 96-well plates. After 24 h incubation, cells were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) in a 2:5 (mol/v) DNA:lipo2000 ratio. Following 24 h culturing, the transfected cells were ready for use.

2.3. BRET assay

To assess GPCR–RAMP interaction, receptor-Rluc8 was transfected at a constant concentration with increasing ratio of RAMP-Ypet from 1:0.25 to 1:16 to COS-7 cells. After transfection, cells were washed and incubated with 80 μL BRET buffer [calcium and magnesium free HBSS buffer (Gibco) supplemented with 10 mmol/L HEPES (Gibco) and 0.1% bovine serum albumin (BSA; Abcone, Shanghai, China), pH 7.4] in a 37 °C incubator for 30 min. Then Rluc8 specific substrate, coelenterazine H (Yeasen Biotech, Shanghai, China), was added to the incubation system with a final concentration of 5 μmol/L. The plates were read after 5 min using an EnVision multilabel instrument (PerkinElmer, Waltham, MA, USA). For titration assay, the signal ratio at 535 nm/470 nm was normalized and the curves were fitted for simple linear regression vs. one-site binding.

For β-arrestin1/2 recruitment, COS-7 cells were transfected with a receptor-Rluc8:RAMP:Venus-β-arrestin1/2 ratio of 1:1:2.
The next day, cells were washed and incubated with 80 μl BRET buffer. Then 10 μl coelenterazine H was added to each well with low light. Measurement was started 5 min thereafter. The initial 15-cycle reads were normalized as baseline and signals of ligand-induced responses were recorded for a total of 70 cycles.

2.4. Immunofluorescence staining

HEK293A cells were seeded in 6-well plates and transfected with 4 μg plasmid containing GPCR-HA and FLAG-RAMP at a ratio of 1:1. After 24 h, cells were collected and reseeded in 96-well plates until the cells reached 50%–70% confluences. They were washed with PBS before fixation with 4% paraformaldehyde for 15 min. Then they were washed three more times and blocked with 5% BSA plus 0.1% Triton X-100 for 1 h at room temperature (RT). Rabbit anti-HA primary antibody (Cell Signaling Technology, Danvers, MA, USA; 1:500) and mouse anti-FLAG primary antibody (Sigma–Aldrich, St. Louis, MO, USA; 1:300) were diluted with incubation buffer (PBS supplemented with 5% BSA) for 1 h followed by 3-time wash. Cells were reacted with 100 μl interaction buffer containing donkey anti-rabbit Alexa 488-conjugated secondary antibody and donkey anti-mouse Alexa 647-conjugated secondary antibody (Invitrogen; diluted 1:1000) at RT for 1 h in the dark. After final washing, nuclei were stained with Hoechst 33,258 for 5 min. Cells were imaged using high-resolution microscope DeltaVision™ Ultra (GE Healthcare, Boston, USA).

2.5. cAMP accumulation

COS-7 cells were seeded in 6-well plates and transfected with 4 μg plasmid containing receptor and RAMP at a ratio of 1:1. After 24 h, cells were collected and reseeded in 384-well plates at a density of 3000 cells/well. Following overnight incubation, cells were washed and incubated with stimulation buffer (calcium and magnesium free HBSS buffer, 5 mM/L HEPES, 0.1% BSA, 0.5 mM/L 3-isobutylene-1-methylxanthine). They were then treated with different concentrations of endogenous ligands for 40 min at RT. The glucagon receptor family preferentially activates Gs which subsequently activates adenylyl cyclase to generate cAMP. To investigate the effect of RAMPs on this parameter, we transiently co-transfected individual receptors and each of the RAMP subtypes to COS-7 cells. As shown in Fig. 3 and Table 2, RAMP3 reduced GIP-elicited cAMP response by ~40-fold while the Emax value remained the same (Fig. 3H). It also decreased GLP-1 and

2.6. Goq activation

HEK293A cells were seeded in 6-well plates and transfected with a plasmid mixture containing receptor:RAMP:Goαq-LgBt:Gβ5:SmBt-Gγ7:Ric-8A at a ratio of 1:1:1:3:3:4. Cells were transferred to 96-well plates at a density of 50,000 cells/well the next day. After 24 h, they were washed and incubated with 80 μl NanoBt buffer (calcium and magnesium free HBSS buffer, supplemented with 10 mM/L HEPES and 0.1% BSA, pH 7.4) in 37 °C for 30 min. Then 10 μL coelenterazine H was added to each well at a working concentration of 5 μmol/L followed by 2 h incubation. The plates were read at 30 s interval for 4 min as baseline, then read for 10 min after addition of ligand.

2.7. Data analysis

Data were analyzed using Prism 8 (GraphPad, San Diego, CA, USA). For signaling assays, data of individual experiments were normalized to the maximum responses in cells expressing only the receptor. Non-linear curve fit was performed using a three-parameter logistic equation [log (agonist vs. response)]. For time–course kinetic traces, the BRET ratio or luciferase value was corrected with post-stimulation basal reading and then normalized to the kinetic traces of each receptor–RAMP pair in the absence of ligand. All data are presented as mean ± standard error of mean (SEM). Significant differences were determined by one-way ANOVA with Dunnett’s test.

3. Results

3.1. GPCR–RAMP interaction

A BRET assay was used to identify the association patterns between the glucagon receptor family members and RAMPs. This technique has been widely applied to study protein–protein interaction through detecting Rluc8 and Ypet attached to individual protein C terminus. We transfected a constant amount of receptor-Rluc8 with an increasing ratio of RAMP-Ypet into COS-7 cells and measured the signal ratio at 535 nm/470 nm. β2-Adrenergic receptor (β2-AR) was employed as negative control to set up the threshold15. CLR, a typical RAMP-interacting GPCR, was utilized as positive control1. All interaction curves reflect the best fit of a comparison between linear and hyperbolic fittings (Fig. 1). The fitting result inclined to the linear relationship was considered negative. For β2-AR, the interaction with RAMPs 1 and 2 showed higher linear fitting which was hyperbolic in the case of RAMP3. Previous reports demonstrated that RAMP3 could translocate to the cell membrane when expressed alone. Higher surface expression of RAMP3 provided more random interactions with membrane receptors than that of RAMP1 and RAMP2, thereby deviating the fitting from linearity7,18,19. Therefore, we set up a threshold of Bmax > 0.35 for RAMP3 interaction: below this value would be regarded negative. Of the protein pairs investigated, GLP-2R and RAMP1 exhibited a poor interaction compared to other pairs (Fig. 1A). It was noted that the interaction ability was negatively correlated with the value of BRET50 (Table 1) which can be rank-ordered as weak interactions with membrane receptors than that of RAMP1 and RAMP2, thereby deviating the fitting from linearity7,18,19. Therefore, we set up a threshold of Bmax > 0.35 for RAMP3 interaction: below this value would be regarded negative. Of the protein pairs investigated, GLP-2R and RAMP1 exhibited a poor interaction compared to other pairs (Fig. 1A). It was noted that the interaction ability was negatively correlated with the value of BRET50 (Table 1) which can be rank-ordered as weak (BRET50 < 5), normal (1 < BRET50 < 5) and strong (BRET50 < 1). GLP-1R/RAMP1, GLP-2R/RAMP2 and SV1/RAMP3 displayed weak interactions while that of GHRHR/RAMP2 and GIPR/RAMP3 were strong. This observation is supported by subsequent immunostaining studies showing the co-localization of members of the glucagon receptor family and RAMPs (Fig. 2). Quantitative analysis of RAMP surface expression suggests that co-transfection of CLR with RAMPs significantly improved the presence of the latter on the cell membrane (Supporting Information Fig. S6). For RAMP1, only co-expression with SCTR promoted cell surface translocation (Fig. S6A). The effect on RAMP2 co-expression is negligible whereas that of GCGR, SV1 and SCTR on RAMP3 expression was negative (Fig. S6B and S6C).

3.2. cAMP accumulation

The glucagon receptor family preferentially activates Goαq which subsequently activates adenylyl cyclase to generate cAMP. To investigate the effect of RAMPs on this parameter, we transiently co-transfected individual receptors and each of the RAMP subtypes to COS-7 cells. As shown in Fig. 3 and Table 2, RAMP3 reduced GIP-elicited cAMP response by ~40-fold while the Emax value remained the same (Fig. 3H). It also decreased GLP-1 and
Figure 1  Screening of the interaction between the glucagon receptor family members and RAMPs. ΔBRET for each receptor–RAMP pair was observed in COS-7 cells. Curves were plotted as the level of increased RAMP:receptor signal ratio and calculated using the best-fit comparison for linearity vs hyperbolic curve fitting (nonlinear fit of one site-binding). Curves are representative for each interaction between receptor and RAMP1 (A), RAMP2 (B) and RAMP3 (C), respectively. CLR was served as positive control (red) and β2-AR was the negative control (blue). Average \( B_{\text{max}} \) and \( \text{BRET}_{50} \) (\( K_d \)) values are provided in Table 1. Data shown are mean ± SEM from at least four independent experiments.
Oxyntomodulin induced cAMP accumulation (by <10-fold; Fig. 3I and J). While RAMP3 had no effect on GHRHR it exhibited a marked response in SV1 expressing cells (Fig. 3G). Both RAMP1 and RAMP2 either caused a slight reduction (Fig. 3I and J) or had no influence on the $E_{\text{max}}$ or $EC_{50}$ values for any receptor.

| Table 1  | Interaction of GPCR–RAMP pairs. |
|----------|----------------------------------|
|          | RAMP1 | RAMP2 | RAMP3 |
| Receptor | $B_{\text{max}}$ | $B_{\text{max}}$ | $B_{\text{max}}$ |
| CLR      | 0.460 ± 0.017 | 0.077 ± 0.016 | 0.468 ± 0.042 | 0.114 ± 0.019 | 0.511 ± 0.058 | 0.087 ± 0.037 |
| $\beta_2$-AR | Linear fit | Linear fit | Linear fit | Linear fit | Linear fit | $<0.35$ | 1.865 ± 0.562 |
| GCGR     | 1.149 ± 0.109 | 1.551 ± 0.362 | 0.578 ± 0.072 | 1.654 ± 0.496 | 1.102 ± 0.165 | 2.340 ± 0.716 |
| GHRHR    | 1.122 ± 0.193 | 2.426 ± 0.837 | 0.393 ± 0.025 | 0.893 ± 0.165 | 0.948 ± 0.139 | 2.090 ± 0.661 |
| SV1      | 1.364 ± 0.244 | 4.398 ± 1.155 | 0.843 ± 0.102 | 2.356 ± 0.581 | 1.842 ± 0.754 | 5.979 ± 3.064 |
| GIPR     | 1.316 ± 0.203 | 4.600 ± 1.016 | 0.474 ± 0.122 | 2.751 ± 1.331 | 0.729 ± 0.061 | 0.352 ± 0.095 |
| GLP-1R   | 2.039 ± 1.234 | 10.898 ± 6.262 | 0.397 ± 0.092 | 2.232 ± 1.079 | 0.862 ± 0.100 | 1.003 ± 0.333 |
| GLP-2R   | Linear fit | Linear fit | 0.567 ± 0.234 | 7.451 ± 3.462 | 0.689 ± 0.128 | 1.655 ± 0.737 |
| SCTR     | 0.573 ± 0.021 | 1.297 ± 0.128 | 0.434 ± 0.051 | 2.407 ± 0.572 | 0.995 ± 0.058 | 1.631 ± 0.232 |

All values are mean ± SEM of at least three independent experiments. Data were calculated using the best-fit comparison for linearity vs. hyperbolic curve fitting (nonlinear fit of one site-binding).

$B_{\text{max}}$, the maximum measured BRET value.

BRET$_{50}$ ($K_d$), the intensity ratio of RAMP:receptor that gives a half of the maximum response.

Figure 2  Co-localization of members of the glucagon receptor family and RAMPs. HEK293A cells were co-transfected with each FLAG-RAMP (red) and GPCR-HA (green) at a 1:1 ratio. After 24 h, each receptor–RAMP pair was stained with anti-HA and anti-FLAG monoclonal antibodies, respectively, using CLR (A) as positive and $\beta_2$-AR (B) as negative controls. Data shows representative results from three independent experiments at GCGR (C), GHRHR (D), SV1 (E), GIPR (F), GLP-1R (G), GLP-2R (H) and SCTR (I). Cells were observed by DeltaVision™ Ultra. Scale bar = 15 μm.
3.3 Gaq activation

Gaq activation after ligand stimulation leads to activation of phospholipase C which cleaves phosphatidylinositol 4,5-bisphosphate to generate diacylglycerol and inositol triphosphate related to Ca2+ mobilization. A NanoBiT assay that fuses the large bit of nanoluciferase to the Gaq-subunit and the small bit to the β-subunit was used to assess the state of Gaq (Fig. 4, Supporting Information Fig. S1 and Table 2). For GCGR, both RAMPs 1 and 3 displayed reduced Emax values upon stimulation by glucagon and oxyntomodulin (Fig. 4D and E). The effects of RAMP1 on glucagon- and oxyntomodulin-induced maximal responses were weaker than that of RAMP3 (70.9 ± 7.3% vs. 42.1 ± 5.2% and 81.7 ± 10.8% vs. 24.5 ± 5%). For GHRHR, no RAMP was able to alter the concentration–response characteristics (Fig. 4F) whereas RAMP3 displayed a negative impact on the Emax stimulated by GLP-1 (63.7 ± 11%) or oxyntomodulin (75.5 ± 17.4%) (Fig. 4G and H). Similar phenomenon was observed with GLP-2R: 47.1 ± 6.8% of the Emax under the influence of RAMP3 (Fig. 4I). Besides, RAMP2 caused a nominal reduction in the potency of GLP-2R.

3.4 β-Arrestin1/2 recruitment

Independent of G protein signaling, β-arrestin recruitment is involved in receptor desensitization and endocytosis. Arrestin 2 (also called β-arrestin1) and arrestin 3 (β-arrestin2) are widely expressed and bind to most GPCRs. We used a BRET assay by attaching Rluc8 to receptor C terminus and Venus to β-arrestin1/2 N terminus (Fig. 5 and 6, Supporting Information Figs. S2 and S3). Both RAMPs 1 and 2 enhanced glucagon-mediated β-arrestin1/2 recruitment by GCGR (160.3 ± 14.7% and 185.5 ± 13%; Fig. 5D and Table 2). The negative impact of
### Table 2: Modulation of signaling profiles of the glucagon receptor family of GPCRs.

| Receptor | Ligand | Interaction | Assay | cAMP accumulation | $E_{\text{max}}$ (%) | $pEC_{50}$ | $E_{\text{max}}$ (%) |
|----------|--------|-------------|-------|-------------------|----------------------|-----------|-------------------|
| CLR | CGRP | Vector | 8.5 ± 0.2 | 20.0 ± 1.2 | N.D. | N.D. | 7.3 ± 1.8 | 16.9 ± 10.6 |
| | | RAMP1 | 9.8 ± 0 | 100 ± 0.8 | 7.2 ± 0.1 | 100 ± 3.7 | 6.9 ± 0.3 | 100 ± 8.6 |
| | | RAMP2 | 10.8 ± 0.1 | 100 ± 2.5 | N.D. | N.D. | 6.8 ± 0.5 | 100 ± 17.2 |
| | | RAMP3 | 10.1 ± 0.1 | 95.6 ± 1.7 | N.D. | N.D. | 6.7 ± 1.4 | 17.9 ± 11.7 |
| | Adrenomedullin | Vector | 9.4 ± 0.2 | 46.3 ± 2.9 | N.D. | N.D. | N.A. | N.A. |
| | | RAMP1 | 10.8 ± 0.1 | 100 ± 0.8 | N.D. | N.D. | N.A. | N.A. |
| | | RAMP2 | 10.1 ± 0.1 | 95.6 ± 1.7 | N.D. | N.D. | N.A. | N.A. |
| $\beta_2$-AR | (-)-Adrenaline | Vector | 9.6 ± 0 | 100 ± 1.3 | 6.9 ± 0.2 | 100 ± 6.7 | 6.2 ± 0.3 | 100 ± 11.5 |
| | | RAMP1 | 9.6 ± 0.1 | 98.9 ± 1.9 | 6.5 ± 0.2 | 102.3 ± 10.3 | 6.2 ± 0.3 | 100 ± 11.5 |
| | | RAMP2 | 9.7 ± 0 | 99.7 ± 1.5 | 6.3 ± 0.4 | 116.4 ± 20.5 | 5.8 ± 0.5 | 83.4 ± 15 |
| | | RAMP3 | 9.7 ± 0.1 | 100.7 ± 2 | 6.9 ± 0.3 | 98.7 ± 11.6 | 6.0 ± 0.4 | 104.6 ± 15.7 |
| GCGR | Glucagon | Vector | 8.5 ± 0.1 | 100 ± 1 | 6.8 ± 0.2 | 100 ± 8.1 | 5.5 ± 0.1 | 100 ± 6.3 |
| | | RAMP1 | 8.4 ± 0.1 | 104.3 ± 2 | 6.7 ± 0.2 | 102.1 ± 7.6 | 5.0 ± 0.1 | 185.5 ± 13.2 |
| | | RAMP2 | 8.6 ± 0.1 | 104.3 ± 2 | 6.7 ± 0.2 | 102.1 ± 7.6 | 5.0 ± 0.1 | 185.5 ± 13.2 |
| | | RAMP3 | 8.3 ± 0.1 | 103.3 ± 1.9 | 7.3 ± 0.3 | 42.1 ± 5.2** | 5.0 ± 0.4 | 107.9 ± 21.2 |
| | Oxyntomodulin | Vector | 8.6 ± 0 | 100 ± 1.2 | 7 ± 0.2 | 100 ± 9.4 | N.D. | N.D. |
| | | RAMP1 | 8.4 ± 0.1 | 103.1 ± 1.7 | 7 ± 0.3 | 81.7 ± 10.8 | N.D. | N.D. |
| | | RAMP2 | 8.5 ± 0.1 | 103.4 ± 2.5 | 7 ± 0.3 | 113 ± 13.6 | N.D. | N.D. |
| | | RAMP3 | 8.4 ± 0.1 | 101.7 ± 2.2 | 9.9 ± 0.4*** | 24.5 ± 5** | N.D. | N.D. |
| GHRHR | GHRH | Vector | 10 ± 0 | 100 ± 1.2 | 10.7 ± 0.2 | 100 ± 6.9 | 5.3 ± 0.6 | 100 ± 25.3 |
| | | RAMP1 | 9.8 ± 0 | 104.1 ± 2 | 11.2 ± 0.3 | 91.8 ± 8.3 | 4.8 ± 0.6 | 123.5 ± 42.2 |
| | | RAMP2 | 10 ± 0 | 101.5 ± 1.4 | 10.5 ± 0.3 | 105.1 ± 9.4 | 4.7 ± 0.4 | 124 ± 3.4 |
| | | RAMP3 | 9.8 ± 0.1 | 100.3 ± 1.5 | 10.9 ± 0.3 | 87.9 ± 8 | 4.4 ± 0.6 | 101.9 ± 45.7 |
| | SV1 | GHRH | 5.9 ± 0 | 100 ± 1.8 | N.A. | N.A. | 5.4 ± 0.3 | 100 ± 11.2 |
| | | RAMP1 | 5.9 ± 0.1 | 100.3 ± 3.4 | N.A. | N.A. | 4.2 ± 0.3 | 188.4 ± 36.8 |
| | | RAMP2 | 5.9 ± 0.1 | 102.4 ± 2.2 | N.A. | N.A. | 4.1 ± 0.3 | 181.8 ± 44.2 |
| | | RAMP3 | 6.4 ± 0.1** | 100.3 ± 2 | N.A. | N.A. | 4.7 ± 0.5 | 168.1 ± 49.1 |
| GIPR | GIP | Vector | 10.3 ± 0 | 100 ± 1.3 | N.A. | N.A. | 4.9 ± 0.3 | 100 ± 17.7 |
| | | RAMP1 | 10.3 ± 0.1 | 99 ± 1.8 | N.A. | N.A. | 5.5 ± 0.4 | 185.5 ± 19.9 |
| | | RAMP2 | 10.2 ± 0 | 99.3 ± 1.2 | N.A. | N.A. | 4.9 ± 0.3 | 82.1 ± 17.4 |
| | GLP-1R | GLP-1 | Vector | 10.6 ± 0.1 | 100 ± 1.8 | 11.8 ± 0.2 | 100 ± 5 | 6.7 ± 0.1 | 100 ± 3.8 |
| | | RAMP1 | 10.3 ± 0.1** | 98.5 ± 1.7 | 11.6 ± 0.3 | 86.2 ± 5.6 | 6.6 ± 0.1 | 106.3 ± 4.7 |
| | | RAMP2 | 10.6 ± 0.1 | 99.4 ± 1.4 | 11.2 ± 0.2 | 83.8 ± 5.3 | 6.5 ± 0.2 | 105 ± 5.9 |
| | | Oxyntomodulin | 8.6 ± 0.1 | 100 ± 1.6 | 10.8 ± 0.2 | 100 ± 5.4 | 5.8 ± 0.2 | 100 ± 12 |
| | | RAMP1 | 8.2 ± 0.1** | 99.8 ± 2.1 | 10.2 ± 0.3 | 107.8 ± 8.4 | 5.9 ± 0.2 | 122.3 ± 11 |
| | | RAMP2 | 8.6 ± 0.1 | 99.6 ± 1.8 | 10.6 ± 0.4 | 102.7 ± 9.5 | 5.7 ± 0.2 | 119.9 ± 12 |
| | GLP-2R | GLP-2 | Vector | 9.7 ± 0.1 | 100 ± 1.4 | 10.5 ± 0.3 | 100 ± 7.5 | 7.1 ± 0.2 | 100 ± 6 |
| | | RAMP1 | 9.7 ± 0.1 | 96.2 ± 2.7 | 9.2 ± 0.2 | 119.2 ± 9.9 | 7 ± 0.1 | 89.5 ± 4 |
| | | RAMP3 | 9.4 ± 0.1 | 98.7 ± 2.7 | 11 ± 0.5 | 47.1 ± 6.8** | 6.8 ± 0.2 | 77.9 ± 5.9 |

(continued on next page)
Supporting Information Table S1 and Fig. 7 show that RAMP has an extensive interaction with the glucagon receptor family members albeit it is rather weak between RAMP1 and GLP-2R. Looking at the subtype specificity, RAMP1 exerts effects on GCGFR and GLP-1R through cAMP production, Glp1 activation and β-arrestin1 recruitment. It appears biased towards cAMP accumulation at GLP-1R compared to GCGFR that trends towards Glp1 activation. RAMP2 only participates in β-arrestin1/2 recruitment by GCGFR, GLP-1R and GLP-2R. RAMP3 demonstrates a broad spectrum of negative modulation covering all three tested pathways involving GCGFR, GIPR, GLP-1R, GLP-2R and SCTR.

Since RAMP3 has a negative impact on GLP-1-induced signaling, it may also affect receptor scavenging. Meanwhile, β-arrestin2 recruitment is increased upon stimulation by oxyntomodulin in the presence of RAMP2. Therefore, we performed ligand-induced internalization assay with GLP-1R in the presence or absence of RAMP2/3. It was found that RAMP did not affect the speed of GLP-1R internalization elicited by GLP-1, while RAMP2 caused a rapid loss of cell surface GLP-1R upon oxyntomodulin stimulation, suggesting that RAMP2 may promote receptor scavenging through β-arrestin recruitment (Supporting Information Fig. S7).

Except for GHRHR, other five family members seem to be functionally modulated by at least one RAMP. Oxyntomodulin is a dual-agonist of GCGFR and GLP-1R\(^24,25\). For GLP-1R, RAMPs 1, 2 and 3 were shown to affect oxyntomodulin-induced cAMP and β-arrestin2 recruitment, while RAMPs 1 and 3, but not RAMP2, only took part in Glp1 pathway at GCGFR. It appears that RAMP is capable of modifying signaling profiles elicited by different ligands on the same receptor. RAMP3 reduced both glucagon- and oxyntomodulin-induced Glp1 responses at GCGFR. RAMP1 suppressed Glp1 response but promoted β-arrestin1 recruitment which could also be enhanced by RAMP2 upon glucagon stimulation. For GLP-1R, RAMPs 1 and 3 caused a decreased cAMP signaling under the influence of either GLP-1 or oxyntomodulin, whereas RAMP2 specifically enhanced oxyntomodulin-stimulated β-arrestin2 recruitment and RAMP3 exerted a negative impact on GLP-1-induced Glp1 activation and β-arrestin2 recruitment. While GIPR-mediated cAMP signaling was weakened by RAMP3, RAMPs 2 and 3 restrained β-arrestin2 recruitment and Glp1 response at GLP-2R. The effects of RAMP3 on β-arrestin1/2 recruitment at both GLP-2R and SCTR were also negative. Although no modulating effect was seen at GHRHR, the impact of RAMP3 on cAMP accumulation at SV1 was noticeable (Fig. 3F and G).

### 4. Discussion

To investigate the role of RAMPs in modulating signaling pathways of the glucagon receptor family of GPCRs, we established a BRET assay to detect interactive pairs. Compared to the results

---

**Table 2 (continued)**

| Receptor | Ligand | Assay | Interaction | cAMP accumulation | β-Are1/2n1 recruitment | Glp1 activation | pEC50 | Emax (%) | pEC50 | Emax (%) | pEC50 |
|----------|--------|-------|-------------|-------------------|-----------------------|----------------|-------|---------|-------|---------|-------|
| SCTR     | Secretin | Vecto | 10.7 ± 0.1 | 96.6 ± 1.5 | 97.4 ± 0.3 | 99.6 ± 1.7 | 7.7 ± 0.6 | 99.4 ± 0.9 | 7.6 ± 0.6 | 99.4 ± 0.9 | 7.6 ± 0.6 |
| SCTR     | Secretin | RAMP1 | 10.7 ± 0.1 | 96.6 ± 1.5 | 97.4 ± 0.3 | 99.6 ± 1.7 | 7.7 ± 0.6 | 99.4 ± 0.9 | 7.6 ± 0.6 | 99.4 ± 0.9 | 7.6 ± 0.6 |
| SCTR     | Secretin | RAMP2 | 10.7 ± 0.1 | 96.6 ± 1.5 | 97.4 ± 0.3 | 99.6 ± 1.7 | 7.7 ± 0.6 | 99.4 ± 0.9 | 7.6 ± 0.6 | 99.4 ± 0.9 | 7.6 ± 0.6 |
| SCTR     | Secretin | RAMP3 | 10.7 ± 0.1 | 96.6 ± 1.5 | 97.4 ± 0.3 | 99.6 ± 1.7 | 7.7 ± 0.6 | 99.4 ± 0.9 | 7.6 ± 0.6 | 99.4 ± 0.9 | 7.6 ± 0.6 |

\*p < 0.05, **p < 0.01 and ***p < 0.001 vs. at least three independent experiments. Statistical analysis was carried out by Dunnett’s test. 
N.A., no robust stimulation was detected at the highest concentration.
N.D., values that could not be determined without complete curve fit.

---
generated by multiplexed SBA techniques, we confirmed most GPCR–RAMP interactions reported previously. However, the association between GHRHR and RAMP1 was readily observed in this study (Fig. 1A) but was claimed to be insignificant with the SBA assay11, a phenomenon that was noted between GLP-2R and RAMP1 as well (Fig. 1A). Since HEK293T cells utilized in that study express endogenous RAMP1, it may cause non-specific binding to the receptor in question4. High background noise would also reduce protein–protein interaction signal. Such a discrepancy might have been resulted from failure to meet the protein pair distance (<10 nm) required for BRET26,27. Another difference between BRET and SBA is that the former is a quantitative and straightforward measurement in living cells. Although SV1 has a naturally truncated extracellular domain (ECD)17,28, it still showed interactions with all three RAMPs. Studies of the interactome variability by comparing SV1 with GHRHR support the contribution of ECDs to GPCR–RAMP interface29. The published structures of CLR/RAMPs30,31 and chimeric secretin-GLP-1R/RAMP39 indicate that the complex formation requires the association between RAMP and receptor transmembrane domain (TMD). It is likely the high conservation of TMDs among the glucagon receptor family members and the spatial similarity of RAMPs provide a constitutive basis for general interactions between GPCR–RAMP pairs4,32,33.

Interestingly, the interaction between GLP-2R and RAMP1 is different from other pairs. To understand the distinct RAMP1-binding profiles between CLR and GLP-2R, we performed the sequence analysis and structural comparison of the RAMP1-binding sites based on the reported cryo-EM structures (CGRP-CLR–RAMP1–G complex: 6E3Y; GLP-2–GLP-2R–G complex: 7D68; Supporting Information Figs. S4 and S5)31,34. RAMP1 forms extensive hydrophobic interactions with TMs 3–5 as well as several polar contacts with ECL2. However, by adopting unique amino acids that are different from other members in the glucagon receptor family in several positions, direct repulsion between GLP-2R TMD and RAMP1 was observed.

Figure 4  RAMP-mediated modulation of Gαq activation. Measurement of Gαq activation was made in HEK293A cells using a NanoBiT luciferase assay. Gαq activation was elicited by endogenous ligands at CLR (A and B), β2-AR (C), GCGR (D and E), GHRHR (F), GLP-1R (G and H), GLP-2R (I) and SCTR (J). CLR was served as positive control and β2-AR was the negative control. For quantification of concentration–responses, area-under-the-curve data were analyzed after subtracting the post-stimulation baseline. Data were fitted to non-linear regression of three-parameter logistic curve and normalized to the maximal response in cells expressing receptor only (CLR/RAMP1 or CLR/RAMP2 for response elicited by CGRP or adrenomedullin, respectively). Values shown are mean ± SEM from at least three independent experiments.
K337ECL2 and K338ECL2 in ECL2 of GLP-2R do not make polar interaction with RAMP1 while T288 ECL2 and H289ECL2 (CLR) in the equivalent position form the RAMP1-ECL2 interface (Fig. S5B). Compared with the dense contacts between Q140 (RAMP1) and W254 (CLR), the large side-chain of R302 may push the C-terminal of RAMP1 away from the TMD (Fig. S5C). At the C-terminal of TM3 in GLP-2R, proline emerges several residues ahead compared to CLR and other members. It points to a shorter TM3 and conformational change in intracellular loop 2 which may impact the corresponding K142 (RAMP1) interaction (Fig. S5D).

These special structural features of GLP-2R would hinder the binding of RAMP1 to GLP-2R. The results of co-localization experiments (Fig. 2) are consistent with the above findings. However, compared to the BRET assay, analysis of RAMP cell surface expression indicates that only a few receptors exhibited an impact (Supporting Information Fig. S6). For instance, GCGR, SV1 and SCTR downregulated RAMP3 membrane expression, suggesting that cytoplasm remains its action site.

Three signaling events (cAMP generation, Goq activation and β-arrestin1/2 recruitment) were assessed to study the effects of RAMPs on six closely related class B1 receptors. Addition of either GIP or GHRH to cells transfected with respective receptor alone did not affect Goq response at GIPR or SV1 (data not shown). GIPR appears predominantly to signal via Goq rather than Gai and Ca2+ mobilization, whereas the noticeable impact of RAMP3 on GHRH-induced cAMP accumulation at SV1 (Fig. 3G and H) supports the role of ECD in RAMP-modulated G protein activation.

Of interest is that RAMP showed robust association with some of the receptors but failed to affect their signaling pathways. Since RAMP is involved in receptor trafficking, recycling and degradation, pharmacological effects observed in the present study may reflect the dominant action out of its multifaceted functionalities which sometimes relies on the cell line background.
It’s obvious that RAMPs broadly interact with the glucagon receptor family members thereby altering their functions. RAMP1 is in favor of G protein-related pathways, an observation consistent with that found in cells expressing VPAC2R8, whereas RAMP2 mainly mediates β-arrestin recruitment. According to published studies, RAMP2 plays a major role in Gαi/o coupling to VPAC2R and Gαi/q coupling to corticotropin-releasing factor receptor 18, suggesting that its modulation is receptor specific. In addition, increased efficacy of RAMP2 on GCGR was seen in both HEK293T and CHOeK1 cells 38,39. In GCGR-expressing CHOeK1 cells, RAMP2 attenuated Gαq signaling and abolished β-arrestin recruitment38. However, this result could not be reproduced in COS-7 cells. Unlike RAMPs 1 and 2, RAMP3 is indiscriminative of G protein or β-arrestin signaling and the modulation is of repressive nature. Furthermore, our internalization assay demonstrates that the function of RAMP3 is independent of receptor scavenging (Supporting Information Fig. S7).

The effect of RAMP also depends on ligand selectivity40,41. When activated by GLP-1, glucagon or oxyntomodulin (a dual-agonist), GLP-1R and GCGR mediated signaling pathways could be differentially modulated by RAMPs. Structural studies on different receptor–RAMP30,31 and receptor–G protein42 complexes suggest that there may exist two possible mechanisms of RAMP modulation: (i) directly affecting the ligand-receptor binding interface or (ii) indirectly changing receptor conformation38. RAMP may also participate in ligand-induced signal bias. Compared to GLP-1, oxyntomodulin exhibits a bias towards ERK1/2 phosphorylation over cAMP, with similar preference for cAMP relative to iCa2+ signaling. It also displays a stronger...
preference for β-arrestin1/2 recruitment relative to GLP-1.43,44 In this study, both RAMP1 and RAMP3 showed low potency for cAMP production while RAMP2 enhanced β-arrestin2 recruitment at GLP-1R. This feature would promote the bias of oxyntomodulin towards β-arrestins or ERK1/2 phosphorylation over cAMP relative to GLP-1.

Both the glucagon receptor family members and RAMPs are key players of the metabolic and endocrine systems.10 They have an overlap organ distribution including the lung, pancreas, kidney, brain, heart and liver.45–50 Clearly, in-depth analysis of the relationship between GPCR–RAMP pair distribution and physiological relevance is required to understand the significance of RAMP modulation.

5. Conclusions

This present work describes the interactions of RAMPs with members of the glucagon receptor family of GPCRs. Through
verification of previously published RAMP interactome and identification of new GPCR—RAMP pairs, we were able to reveal that RAMP modulates both G protein dependent and independent signaling pathways in a receptor-specific manner.

**Acknowledgments**

This work was partially supported by the National Key R&D Programs of China (2018YFA0507000, Ming-Wei Wang); the National Science Foundation of China grants (81773792, Dehua Yang; 81973373 Dehua Yang; 81872915, Ming-Wei Wang; and 82073904, Ming-Wei Wang); National Science and Technology Major Project of China—Key New Drug Creation and Manufacturing Program (2018ZX09735—001, Ming-Wei Wang and 2018ZX09711002-002-005, Dehua Yang); and the Novo Nordisk-CAS Research Fund (NNCAS-2017-1CC to Dehua Yang).

**Author contributions**

Lijun Shao, Yan Chen, Shikai Zhang and Zhihui Zhang performed the experiments; Lijun Shao, Yan Chen, Yongbing Cao, Dehua Yang and Ming-Wei Wang analyzed the data; Dehua Yang supervised functional studies; Lijun Shao, Yan Chen and Ming-Wei Wang drafted the manuscript; Ming-Wei Wang designed the experiments, oversaw the project and finalize the manuscript with inputs from all the authors.

**Conflicts of interest**

The authors declare no competing interests.

**Appendix A. Supporting information**

Supporting data to this article can be found online at https://doi.org/10.1016/j.apsb.2021.07.028.

**References**

1. McLatchie LM, Fraser NJ, Main MJ, Wise A, Brown J, Thompson N, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. *Nature* 1998;393:333—9.
2. Flahaut M, Rossier BC, Firsov D. Respective roles of calcitonin-receptor-like receptor (CRLR) and receptor activity-modifying proteins (RAMP) in cell surface expression of CRLR/RAMP heterodimeric receptors. *J Biol Chem* 2002;277:14731—7.
3. Watkins HA, Chakravarty M, Abbhayawardana RS, Gingell JJ, Gareja M, Pardamwar M, et al. Receptor activity-modifying proteins 2 and 3 generate adrenomedullin receptor subtypes with distinct molecular properties. *J Biol Chem* 2016;291:11657—75.
4. Hay DL, Pioszak AA. Receptor activity-modifying proteins (RAMPs): new insights and roles. *Annu Rev Pharmacol Toxicol* 2016;56:469—87.
5. Christophouls G, Perry KJ, Morfis M, Tilakaratne N, Gao Y, Fraser NJ, et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. *Mol Pharmacol* 1999;56:235—42.
6. Hay DL, Christophouls G, Christophouls A, Sexton PM. Amylin receptors: molecular composition and pharmacology. *Biochem Soc Trans* 2004;32:865—7.
7. Christophouls A, Christophouls G, Morfis M, Udawela M, Laburthe M, Couvineau A, et al. Novel receptor partners and function of receptor activity-modifying proteins. *J Biol Chem* 2003;278:3293—7.
8. Wootten D, Lindmark H, Kadmiel M, Willcockson H, Caron KM, Barwell J, et al. Receptor activity-modifying proteins (RAMPs) interact with the VPAC2 receptor and CRF1 receptors and modulate their function. *Br J Pharmacol* 2013;168:822—34.
9. Harikumar KG, Simms J, Christopoulos G, Sexton PM, Miller LJ. Molecular basis of association of receptor activity-modifying protein 3 with the family B G protein-coupled secretin receptor. *Biochemistry* 2009;48:11773—85.
10. Serafin DS, Harris NR, Nielsen NR, Mackie DJ, Caron KM. Dawn of a new RAMPPage. *Trends Pharmacol Sci* 2020;41:249—65.
11. Lorenzen E, Dodig-Crnković T, Kotliar IB, Pin E, Ceraudo E, Vaughan RD, et al. Multiplexed analysis of the secretin-like GPCR—RAMP interactome. *Sci Adv* 2019;5:eaaaw2778.
12. Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B, et al. International union of pharmacology. XXXV. The glucagon receptor family. *Pharmacol Rev* 2003;55:167—94.
13. Ma L, Pei G, β-Arrestin signaling and regulation of transcription. *J Cell Sci* 2007;120:213—8.
14. Wootten D, Miller LJ, Koole C, Christopoulos A, Sexton PM. Allosteric and biased agonism at class B G protein-coupled receptors. *Chem Rev* 2017;117:111—38.
15. Routledge SJ, Ladds G, Poyner DR. The effects of RAMPs upon cell signalling. *Mol Cell Endocrinol* 2017;449:12—20.
16. Hay DL, Walker CS, Gingell JJ, Ladds G, Reynolds CA, Poyner DR. Receptor activity-modifying proteins; multifunctional G protein-coupled receptor accessory proteins. *Biochem Soc Trans* 2016;44:568—73.
17. Rekasi Z, Czompoly T, Schally AV, G H. Isolation and sequencing of the novel receptor partners and function of receptor activity-modifying proteins (RAMP) in cell surface expression of CRLR/RAMP heterodimeric receptors. *J Biol Chem* 2003;278:333—7.
18. Mackie DL, Nielsen NR, Harris M, Singh S, Davis RB, Dy D, et al. RAMP3 determines rapid recycling of atypical chemokine receptor-3 for guided angiogenesis. *Proc Natl Acad Sci U S A* 2000;97:10561—6.
19. Bomberger JM, Parameswaran N, Hall CS, Aiyar N, Spielman WS. Novel function for receptor activity-modifying proteins (RAMPs) in post-endocytic receptor trafficking. *J Biol Chem* 2005;280:9297—307.
20. Chen Y, Granger AJ, Tran T, Saulnier JL, Kirkwood A, Sabatini BL. Endogenous Goαi-coupled neuromodulator receptors activate protein kinase A. *Neuron* 2017;96:1070—1083 e5.
21. Zhao P, Liang YL, Belousoff MJ, Deganutti G, Fletcher MM, Willard FS, et al. Activation of the GLP-1 receptor by a non-peptidic agonist. *Nature* 2020;577:432—6.
22. Tian X, Kang DS, Benovic JL. β-Arrestins and G protein-coupled receptor trafficking. *Handb Exp Pharmacol* 2014;219:173—86.
23. Lefkowitz RJ, Shenyo SK. Transduction of receptor signals by β-arrestins. *Science* 2005;308:512—7.
24. Cai X, Li C, Zhou J, Dai Y, Avraham Y, Sun L, et al. Novel glucagon- and OXM-based peptides acting through glucagon and GLP-1 receptors with body weight reduction and anti-diabetic properties. *Bioorg Chem* 2020;95:103538.
25. Poci A. Unraveling oxyntomodulin, GLP1’s enigmatic brother. *J Endocrinol* 2012;215:335—46.
26. Roed SN, Orgaard A, Jorgensen R, De Meyts P. Receptor oligomerization in family B1 of G-protein-coupled receptors: focus on DRET investigations and the link between GPCR oligomerization and binding cooperativity. *Front Endocrinol (Lausanne)* 2012;3:62.
27. Achour L, Kamal M, Jockers R, Marullo S. Using quantitative BRET to assess G protein-coupled receptor homo- and heterodimerization. *Methods Mol Biol* 2011;756:183—200.
28. Barabatuts N, Tseliou E, Schally AV, Koulhsiri S, Kalofoutis A, H K. Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor. *Proc Natl Acad Sci U S A* 2007;104:5575—9.
29. Bailey S, Harris M, Barkan K, Winfield I, Harper MT, Simms J, et al. Interactions between RAMP2 and CRF receptors: the effect of...
receptor subtypes, splice variants and cell context. *Biochim Biophys Acta Biomembr* 2019;1861:997–1003.

30. Liang YL, Belousoff MJ, Fletcher MM, Zhang X, Khoshouei M, Deganutti G, et al. Structure and dynamics of adrenomedullin receptors AM1 and AM2 reveal key mechanisms in the control of receptor phenotype by receptor activity-modifying proteins. *ACS Pharmacol Transl Sci* 2020;3:263–84.

31. Liang YL, Khoshouei M, Fletcher MM, Zhang X, Khoshouei M, Deganutti G, et al. Cryo-EM structure of the active, G13-protein complexed, human CGRP receptor. *Nature* 2018;561:492–7.

32. de Graaf C, Song G, Cao C, Zhao Q, Wang MW, Wu B, et al. Extending the structural view of class B GPCRs. *Trends Biochem Sci* 2017;42:946–60.

33. Zhao LH, Yin Y, Yang D, Liu B, Hou L, Wang X, et al. Differential requirement of the extracellular domain in activation of class B G protein-coupled receptors. *J Biol Chem* 2016;291:15119–30.

34. Sun W, Chen LN, Zhou Q, Zhao LH, Yang D, Zhang H, et al. A unique hormonal recognition feature of the human glucagon-like peptide-2 receptor. *Cell Res* 2020;30:1098–108.

35. Josephs TM, Belousoff MJ, Liang YL, Piper SJ, Cao J, Garama DJ, et al. Structure and dynamics of the CGRP receptor in apo and peptide-bound forms. *Science* 2021;372:eabf7258.

36. Adriaanssens AE, Biggs EK, Darwish T, Tadross J, Sukthankar T, Girish M, et al. Glucose-dependent insulino tropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake. *Cell Metabol* 2019;30:987–996 e6.

37. Volz A, Göke R, Lankat-Buttgereit B, Fehmann HC, Bode HP, B G. Molecular cloning, functional expression, and signal transduction of the GIP-receptor cloned from a human insulinoma. *FEBS Lett* 1995;373:23–9.

38. Cegla J, Jones BJ, Gardiner JV, Hodson DJ, Marjot T, McGlone ER, et al. RAMP2 influences glucagon receptor pharmacology via trafficking and signaling. *Endocrinology* 2017;158:2680–93.

39. Weston C, Lu J, Li N, Barkan K, Richards GO, Roberts DJ, et al. Modulation of glucagon receptor pharmacology by receptor activity-modifying protein-2 (RAMP2). *J Biol Chem* 2015;290:23009–22.

40. Moad HE, Pioszak AA. Selective CGRP and adrenomedullin peptide binding by tethered RAMP-calci tonsin receptor-like receptor extra cellular domain fusion proteins. *Protein Sci* 2013;22:1775–85.

41. Boe JM, Warner ML, Roehrkasse AM, Hay DL, Pioszak AA. Probing the mechanism of receptor activity-modifying protein modulation of GPCR ligand selectivity through rational design of potent adrenomedullin and calcitonin gene-related peptide antagonists. *Mol Pharmacol* 2018;93:355–67.

42. Qiao A, Han S, Li X, Li Z, Zhao P, Dai A, et al. Structural basis of G and G recognition by the human glucagon receptor. *Science* 2020;367:1346–52.

43. Jorgensen R, Kubale V, Vrecl M, Schwart TW, Elling CE. Oxyntomodulin differentially affects glucagon-like peptide-1 receptor β-arrestin recruitment and signaling through Gαs. *J Pharmacol Exp Therapeut* 2007;322:148–54.

44. Willard FS, Wootten D, Showalter AD, Savage EE, Ficorilli J, Farb TB, et al. Small molecule allosteric modulation of the glucagon-like peptide-1 receptor enhances the insulino tropic effect of oxyntomodulin. *Mol Pharmacol* 2012;82:1066–73.

45. Yusta B, Matthews D, Koehler JA, Pujadas G, Kaur KD, Drucker DJ. Localization of glucagon-like peptide-2 receptor expression in the mouse. *Endocrinology* 2019;160:1950–63.

46. Perez-Ibave DC, Garza-Rodriguez ML, Perez-Mayaa AA, Rodriguez-Sanchez IP, Luna-Munoz M, Martinez-Moreno CG, et al. Expression of growth hormone and growth hormone receptor genes in human eye tissues. *Exp Eye Res* 2019;181:61–71.

47. Kopin AS, Wheeler MB, Ab L. Secretin: structure of the precursor and tissue distribution of the mRNA. *Proc Natl Acad Sci U S A* 1990;87:2299–303.

48. Yang DH, Zhou CH, Liu Q, Wang MW. Landmark studies on the glucagon subfamily of GPCRs: from small molecule modulators to a crystal structure. *Acta Pharmacol Sin* 2015;36:1033–42.

49. Parameswaran N, Spielman WS. RAMPs: the past, present and future. *Trends Biochem Sci* 2006;31:631–8.

50. Adams JM, Pei H, Sandoval DA, Seeley RJ, Chang RB, Liberles SD, et al. Liraglutide modulates appetite and body weight through glucagon-like peptide 1 receptor-expressing glutamatergic neurons. *Diabetes* 2018;67:1538–48.